NUWIQ® – Safety in Previously Treated Patients (PTPs)

ZERO Inhibitors in Previously Treated Patients (PTPs) upon Switching to NUWIQ1

  • NUWIQ was shown to be safe in clinical studies that included 135 previously treated patients (PTPs)
  • FVIII levels can be safely and accurately measured with both the chromogenic and one-stage assays
    • No serious or severe reactions to NUWIQ in clinical studies, and no deaths reported
Inhibitors after switching to NUWIQ

Find out about the safety of NUWIQ in previously untreated patients (PUPs)

See Final NuProtect Study Results
  1. NUWIQ full Prescribing Information. Paramus, NJ: Octapharma; rev 2021.